215,000 Shares in Immuneering Corporation $IMRX Purchased by DCF Advisers LLC

DCF Advisers LLC bought a new position in shares of Immuneering Corporation (NASDAQ:IMRX) in the fourth quarter, Holdings Channel.com reports. The institutional investor bought 215,000 shares of the company’s stock, valued at approximately $1,415,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of IMRX. Jane Street Group LLC acquired a new stake in shares of Immuneering during the first quarter worth about $32,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Immuneering during the third quarter worth about $35,000. Mercer Global Advisors Inc. ADV purchased a new position in Immuneering during the third quarter valued at approximately $70,000. Moors & Cabot Inc. purchased a new position in Immuneering during the third quarter valued at approximately $77,000. Finally, XTX Topco Ltd purchased a new position in Immuneering during the second quarter valued at approximately $90,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Stock Performance

NASDAQ IMRX opened at $3.92 on Thursday. The stock’s fifty day moving average is $5.21 and its two-hundred day moving average is $5.46. The firm has a market capitalization of $253.62 million, a P/E ratio of -3.35 and a beta of 0.38. Immuneering Corporation has a fifty-two week low of $1.66 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.09. As a group, sell-side analysts forecast that Immuneering Corporation will post -1.12 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Wall Street Zen upgraded Immuneering from a “sell” rating to a “hold” rating in a research report on Sunday, April 19th. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Immuneering in a research report on Monday, March 9th. Chardan Capital reiterated a “buy” rating and set a $20.00 price target on shares of Immuneering in a research report on Tuesday, May 19th. Oppenheimer reiterated an “outperform” rating on shares of Immuneering in a research report on Monday, June 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research report on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.50.

Immuneering Company Profile

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.